ESC Guidelines 2389 disclosure forms are kept on file at the European Heart House,
headquarters of the ESC. Any changes in conflict of interest that arise during the writing …

PCI-assigned patients, just 0.5% developed CS in the group randomized 2 hours from
symptom onset. A major focus of public health campaigns is the very early recognition and …

Background In patients who have vascular disease or high-risk diabetes without heart
failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and morbidity from …

Document Reviewers: Sigmund Silber (CPG Review Coordinator)(Germany), Frank V.
Aguirre (USA), Nawwar Al-Attar (France), Eduardo Alegria (Spain), Felicita Andreotti (Italy) …

Summary Calcium/calmodulin (Ca 2+/CaM)-dependent protein kinase II (CaMKII) couples
increases in cellular Ca 2+ to fundamental responses in excitable cells. CaMKII was …

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors reduce major
cardiovascular events, but are not tolerated by about 20% of patients. We therefore …

Modern management of acute myocardial infarction is built on a clinical evidence base
drawn from many studies undertaken over the past three decades. The evolution in clinical …

Background—Although mortality after myocardial infarction (MI) has declined in the United
States in recent decades, there have been few community-based investigations of the long …

The increase in heart failure (HF) rates throughout the developed and developing regions of
the world poses enormous challenges for caregivers, researchers, and policymakers …

Cell therapy is a promising option for treating ischemic diseases and heart failure. Adult
stem and progenitor cells from various sources have experimentally been shown to augment …